Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1101-1120 of 2,251 trials

Bladder Cancer: Mitomycin C Treatment Study

We are studying whether a new way to deliver mitomycin C before bladder surgery can lower the risk of cancer returning or worsening in patients with non-muscle invasive bladder tumors.

Non-Muscle Invasive Bladder Tumors>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyUrology

Neuroendocrine Neoplasms: Metronomic Temozolomide Study

We are investigating the effects of low-dose Temozolomide in patients with advanced neuroendocrine neoplasms who are not fit for traditional treatments. The goal is to see if this approach can improve survival and quality of life.

Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology

Pain Relief After Esophageal Procedure: Levobupivacaine Study

We are testing a local anesthetic to see if it helps reduce pain after endoscopic submucosal dissection for esophageal lesions. The study will also look at its safety and impact on recovery time.

Visible Esophageal Lesions (Pre-cancerous)>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal MedicineOtolaryngology

Advanced Melanoma: Relatlimab with Nivolumab Study

We are investigating whether combining Relatlimab with Nivolumab helps people with untreated advanced melanoma live longer and have better outcomes than Nivolumab alone.

Metastatic Melanoma1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Angelman Syndrome: GTX-102 Treatment Study

We are investigating the long-term safety and effectiveness of GTX-102 for individuals with Angelman Syndrome. The study looks at improvements in cognitive function, communication, and motor skills.

Angelman's SyndromeConfirmation phase (III)No PlaceboInvestigational MedicinesNeurology

Cytoreductive Surgery: Albumin and Ringer Lactate Study

We are testing whether a combination of 20% albumin and Ringer Lactate improves recovery after surgery for patients with peritoneal carcinosis. This study compares it to Ringer Lactate alone to see which is more effective.

Peritoneal Carcinomatosis>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteGastroenterologyGynecology and ObstetricsInternal MedicineOncology

Regorafenib for Recurrent Grade 2 and 3 Meningioma

We are studying whether Regorafenib can help patients with recurrent grade 2 and 3 meningiomas live longer without disease progression after surgery and radiotherapy. The trial also looks at overall survival, quality of life, and potential side effects.

Malignant Meningioma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Glioblastoma Treatment: Olaptesed Pegol with Radiation

We are studying the safety and effectiveness of olaptesed pegol combined with radiation therapy for patients with newly diagnosed glioblastoma and unmethylated MGMT promoter. This trial also explores how different doses may impact treatment outcomes.

Glioblastoma6-12 monthsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Diffuse Large B-Cell Lymphoma: Epcoritamab Plus Lenalidomide

We are studying whether a new combination of epcoritamab and lenalidomide can improve survival rates for adults with relapsed or refractory diffuse large B-cell lymphoma compared to standard treatments.

Relapsed or Refractory Diffuse Large B-Cell Lymphoma6-12 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Lymphoma Treatment: MK-3475A Study

We are testing a new formulation of pembrolizumab for patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal large B-cell lymphoma. The study aims to evaluate its effectiveness and safety compared to existing treatments.

Relapsed or Refractory Classical Hodgkin LymphomaRelapsed or Refractory Primary Mediastinal Large B-cell Lymphoma>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Gastric Cancer: New Drug Combinations

We are studying new combinations of medications alongside chemotherapy for people with advanced gastric or gastroesophageal junction cancer. The goal is to see if these combinations improve treatment outcomes and safety.

Gastric AdenocarcinomaEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Dexamethasone for Advanced Multiple Myeloma

We are studying a free treatment regimen of Dexamethasone for patients with advanced relapsed or refractory multiple myeloma. The goal is to see how well it works in improving response rates and quality of life.

Multiple Myeloma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Advanced High-Grade Osteosarcoma: OMO-103 Treatment Study

We are testing a new drug, OMO-103, to see if it can help treat advanced high-grade osteosarcoma in patients aged 12-15. The study will assess its safety and how it impacts the patients' quality of life.

Metastatic Osteosarcoma3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Mucopolysaccharidosis Type II: DNL310 vs Idursulfase

We are studying a new treatment, DNL310, for children and young adults with Mucopolysaccharidosis Type II to see if it works better than the current treatment, Idursulfase, in improving brain and physical health.

Hunter's Syndrome>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyNeurology

Acute Myeloid Leukemia: Venetoclax and Azacitidine with Cusatuzumab

We are studying whether adding cusatuzumab to standard treatment helps newly diagnosed AML patients who can't have intensive therapy. This trial will also look at the safety and effectiveness of this combination.

Acute Myeloid LeukemiaEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Neuroendocrine Tumors: Lutathera® Treatment Study

We are studying whether additional cycles of Lutathera® can help patients with new progression of intestinal well-differentiated neuroendocrine tumors. This trial compares the treatment to active monitoring to see which approach is more effective.

Neuroendocrine Tumor>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Sedation Methods in TAVR Procedures

We are comparing different sedation techniques for patients undergoing Transcatheter Aortic Valve Replacement. The goal is to see if one method reduces breathing problems and confusion after the procedure.

Aortic Stenosis1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyGastroenterologyInternal MedicineOtolaryngologyPsychiatry

Advanced Prostate Cancer: Debio 4228 Study

We are testing a new medication, Debio 4228, to see if it effectively lowers hormone levels in men with advanced prostate cancer. The study will also look at how well the medication is tolerated and its safety profile.

Advanced Prostate Cancer6-12 monthsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Ampullary Adenocarcinoma: mFOLFIRINOX vs. Gemcitabine or Capecitabine

We are studying whether a combination chemotherapy can improve survival rates for patients after surgery for ampullary adenocarcinoma. The trial also looks at quality of life and side effects compared to standard treatments.

Ampullary Adenocarcinoma3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Ovarian and Lung Cancer: TUB-040 Treatment Study

We are investigating a new antibody-guided drug for patients with therapy-resistant ovarian or lung cancer. The study aims to assess its safety and how well it works compared to existing treatments.

Platinum-Resistant High-Grade Ovarian Cancer and Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementGynecology and ObstetricsOncologyPulmonology